Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C A Seipp

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Cancer|April 1, 1981
A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapyA E Chang, D J Shiling, R C Stillman, et al.
Archives of Surgery (Chicago, Ill. : 1960)|December 1, 1986
Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomasS E Ettinghausen, R O Bonow, S T Palmeri, et al.
Cancer|December 15, 1986
Clinical effects and toxicity of interleukin-2 in patients with cancerM T Lotze, Y L Matory, A A Rayner, et al.
Annals of Surgery|October 1, 1989
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patientsS A Rosenberg, M T Lotze, J C Yang, et al.
Surgery|August 1, 1986
A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2S A Rosenberg, M T Lotze, L M Muul, et al.
Annals of Internal Medicine|December 1, 1979
Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluationA E Chang, D J Shiling, R C Stillman, et al.
Cancer|February 15, 1995
The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinomaM P MacFarlane, J C Yang, A S Guleria, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1985
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2M T Lotze, Y L Matory, S E Ettinghausen, et al.
Annals of Internal Medicine|September 1, 1987
The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cellsK D Denicoff, D R Rubinow, M Z Papa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1985
Patterns of recurrence in patients with high-grade soft-tissue sarcomasD A Potter, J Glenn, T Kinsella, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Cancer|April 1, 1981
A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapyA E Chang, D J Shiling, R C Stillman, et al.
Archives of Surgery (Chicago, Ill. : 1960)|December 1, 1986
Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomasS E Ettinghausen, R O Bonow, S T Palmeri, et al.
Cancer|December 15, 1986
Clinical effects and toxicity of interleukin-2 in patients with cancerM T Lotze, Y L Matory, A A Rayner, et al.
Annals of Surgery|October 1, 1989
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patientsS A Rosenberg, M T Lotze, J C Yang, et al.
Surgery|August 1, 1986
A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2S A Rosenberg, M T Lotze, L M Muul, et al.
Annals of Internal Medicine|December 1, 1979
Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluationA E Chang, D J Shiling, R C Stillman, et al.
Cancer|February 15, 1995
The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinomaM P MacFarlane, J C Yang, A S Guleria, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1985
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2M T Lotze, Y L Matory, S E Ettinghausen, et al.
Annals of Internal Medicine|September 1, 1987
The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cellsK D Denicoff, D R Rubinow, M Z Papa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1985
Patterns of recurrence in patients with high-grade soft-tissue sarcomasD A Potter, J Glenn, T Kinsella, et al.
Pageof 4